Literature DB >> 23714382

Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort.

Srinivas Gaddam1, Mandeep Singh, Gokulakrishnan Balasubramanian, Prashanthi Thota, Neil Gupta, Sachin Wani, April D Higbee, Sharad C Mathur, John D Horwhat, Amit Rastogi, Patrick E Young, Brooks D Cash, Ajay Bansal, John J Vargo, Gary W Falk, David A Lieberman, Richard E Sampliner, Prateek Sharma.   

Abstract

BACKGROUND & AIMS: Recent population-based studies have shown a low risk of esophageal adenocarcinoma (EAC) in patients with nondysplastic Barrett's esophagus (NDBE). We evaluated whether persistence of NDBE over multiple consecutive surveillance endoscopic examinations could be used in risk stratification of patients with Barrett's esophagus (BE).
METHODS: We performed a multicenter outcomes study of a large cohort of patients with BE. Based on the number of consecutive surveillance endoscopies showing NDBE, we identified 5 groups of patients. Patients in group 1 were found to have NDBE at their first esophagogastroduodenoscopy (EGD). Patients in group 2 were found to have NDBE on their first 2 consecutive EGDs. Similarly, patients in groups 3, 4, and 5 were found to have NDBE on 3, 4, and 5 consecutive surveillance EGDs. A logistic regression model was built to determine whether persistence of NDBE independently protected against development of cancer.
RESULTS: Of a total of 3515 patients with BE, 1401 patients met the inclusion criteria (93.3% white; 87.5% men; median age, 60 ±17 years). The median follow-up period was 5 ± 3.9 years (7846 patient-years). The annual risk of EAC in groups 1 to 5 was 0.32%, 0.27%, 0.16%, 0.2%, and 0.11%, respectively (P for trend = .03). After adjusting for age, sex, and length of BE, persistence of NDBE, based on multiple surveillance endoscopies, was associated with a gradually lower likelihood of progression to EAC.
CONCLUSIONS: Persistence of NDBE over several endoscopic examinations identifies patients who are at low risk for development of EAC. These findings support lengthening surveillance intervals or discontinuing surveillance of patients with persistent NDBE.
Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BE; Barrett's Esophagus; Barrett's esophagus; CI; Dysplasia; EAC; EGD; Esophageal Adenocarcinoma; HGD; IQR; LGD; NDBE; OR; PPI; Risk; confidence interval; esophageal adenocarcinoma; esophagogastroduodenoscopy; high-grade dysplasia; interquartile range; low-grade dysplasia; nondysplastic Barrett's esophagus; odds ratio; proton pump inhibitor

Mesh:

Year:  2013        PMID: 23714382     DOI: 10.1053/j.gastro.2013.05.040

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   33.883


  29 in total

1.  Quality indicators for the management of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium.

Authors:  Prateek Sharma; David A Katzka; Neil Gupta; Jaffer Ajani; Navtej Buttar; Amitabh Chak; Douglas Corley; Hashem El-Serag; Gary W Falk; Rebecca Fitzgerald; John Goldblum; Frank Gress; David H Ilson; John M Inadomi; Ernest J Kuipers; John P Lynch; Frank McKeon; David Metz; Pankaj J Pasricha; Oliver Pech; Richard Peek; Jeffrey H Peters; Alessandro Repici; Stefan Seewald; Nicholas J Shaheen; Rhonda F Souza; Stuart J Spechler; Prashanth Vennalaganti; Kenneth Wang
Journal:  Gastroenterology       Date:  2015-08-19       Impact factor: 22.682

2.  Motion sensing superpixels (MOSES) is a systematic computational framework to quantify and discover cellular motion phenotypes.

Authors:  Felix Y Zhou; Carlos Ruiz-Puig; Richard P Owen; Michael J White; Jens Rittscher; Xin Lu
Journal:  Elife       Date:  2019-02-26       Impact factor: 8.140

Review 3.  Recent developments in pathogenesis, diagnosis and therapy of Barrett's esophagus.

Authors:  Magnus Halland; David Katzka; Prasad G Iyer
Journal:  World J Gastroenterol       Date:  2015-06-07       Impact factor: 5.742

4.  The Annual Risk of Esophageal Adenocarcinoma Does Not Decrease Over Time in Patients With Barrett's Esophagus.

Authors:  Theresa Nguyen; Aaron P Thrift; Xiaoying Yu; Zhigang Duan; Hashem B El-Serag
Journal:  Am J Gastroenterol       Date:  2017-02-28       Impact factor: 10.864

5.  The prevalence of Barrett's-esophagus-associated dysplasia in Puerto Rico.

Authors:  Priscilla Magno; Lorena González; Marcia Cruz-Correa; Erick Suárez
Journal:  P R Health Sci J       Date:  2014-12       Impact factor: 0.705

6.  Evaluation of Mutational Testing of Preneoplastic Barrett's Mucosa by Next-Generation Sequencing of Formalin-Fixed, Paraffin-Embedded Endoscopic Samples for Detection of Concurrent Dysplasia and Adenocarcinoma in Barrett's Esophagus.

Authors:  Armando Del Portillo; Stephen M Lagana; Yuan Yao; Takeshi Uehara; Nirag Jhala; Tapan Ganguly; Peter Nagy; Jorge Gutierrez; Aesis Luna; Julian Abrams; Yang Liu; Randall Brand; Jorge L Sepulveda; Gary W Falk; Antonia R Sepulveda
Journal:  J Mol Diagn       Date:  2015-06-08       Impact factor: 5.568

7.  Barrett's Esophagus.

Authors:  Shanmugarajah Rajendra; Prateek Sharma
Journal:  Curr Treat Options Gastroenterol       Date:  2014-06

8.  Single center experience of endoscopic submucosal dissection (ESD) in early Barrett's adenocarcinoma.

Authors:  S Höbel; P Dautel; R Baumbach; K-J Oldhafer; A Stang; B Feyerabend; N Yahagi; C Schrader; S Faiss
Journal:  Surg Endosc       Date:  2014-10-08       Impact factor: 4.584

Review 9.  Barrett's esophagus in 2016: From pathophysiology to treatment.

Authors:  Irene Martinucci; Nicola de Bortoli; Salvatore Russo; Lorenzo Bertani; Manuele Furnari; Anna Mokrowiecka; Ewa Malecka-Panas; Vincenzo Savarino; Edoardo Savarino; Santino Marchi
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-05-06

Review 10.  Barrett oesophagus in 2013: risk stratification and surveillance in Barrett oesophagus.

Authors:  Emmanuel C Gorospe; Kenneth K Wang
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-12-10       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.